Precigen (NASDAQ:PGEN – Get Free Report) is projected to post its quarterly earnings results before the market opens on Wednesday, March 19th. Analysts expect Precigen to post earnings of ($0.06) per share and revenue of $1.30 million for the quarter.
Precigen Stock Performance
Shares of Precigen stock opened at $1.78 on Tuesday. The firm has a market cap of $521.31 million, a PE ratio of -3.24 and a beta of 1.58. The business’s 50 day simple moving average is $1.56 and its 200 day simple moving average is $1.13. Precigen has a 52-week low of $0.65 and a 52-week high of $2.17.
Wall Street Analyst Weigh In
PGEN has been the topic of a number of recent research reports. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective (up from $4.00) on shares of Precigen in a report on Thursday, January 23rd. JMP Securities reiterated a “market outperform” rating and issued a $5.00 price target on shares of Precigen in a research note on Tuesday, January 14th. Two equities research analysts have rated the stock with a sell rating and four have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $7.00.
About Precigen
Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.
Recommended Stories
- Five stocks we like better than Precigen
- Value Investing: Is it a Good Strategy in 2022? (Hint: Always)
- Can TikTok Stock Picks Really Make You Rich?
- How to Use High Beta Stocks to Maximize Your Investing Profits
- The “Quality” Rotation: Back to Basics Investing
- Short Selling: How to Short a Stock
- Occidental Petroleum: 4 Reasons to Love These Prices
Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.